Loading patent…
AssigneeIDEC Pharmaceuticals Corporation
InventorsPeter Brams, Soulaima Salim Chamat, Li-Zhen Pan, Edward E. Walsh, Cheryl Janne Heard, Roland Anthony Newman
Estimating the term…
A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein about 2.times.10.sup.-9 to 10.sup.-10 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.
A human monoclonal antibody which specifically binds the respiratory syncytial virus fusion protein and which possesses an affinity (Kd) for the respiratory syncytial virus fusion protein of about 2.times.10.sup.-9 to 10.sup.-10 molar.
A human monoclonal antibody which specifically binds to the respiratory syncytial virus fusion protein which is selected from the group consisting of RF-1, RF-2 and recombinant human monoclonal antibodies which contain the variable heavy and light domains of either RF-1 or RF-2.
A pharmaceutical composition suitable for preventing or treating respiratory syncytial virus infection in susceptible or respiratory syncytial virus infected persons which comprises a prophylactically or therapeutically effective amount of human monoclonal antibodies which neutralize respiratory syncytial virus in vitro and which possess an affinity (Kd) for the respiratory syncytial virus fusion protein of about 2.times.10.sup.-9 to 10.sup.-10 molar and a pharmaceutically acceptable carrier.
A composition comprising human monoclonal antibodies which possess an affinity (Kd) for the respiratory syncytial virus fusion protein of about 2.times.10.sup.-9 to 10.sup.-10 molar and a carrier.
Dependencies are inferred from the claim text.